€118.60
0.08% yesterday
Paris, May 02, 05:35 pm CET
ISIN
FR0013280286
Symbol
BIM
Sector

bioMerieux SA Stock price

€118.60
+1.50 1.28% 1M
+15.70 15.26% 6M
+15.10 14.59% YTD
+19.75 19.98% 1Y
+28.28 31.31% 3Y
+5.60 4.96% 5Y
+86.67 271.48% 10Y
Paris, Closing price Fri, May 02 2025
-0.10 0.08%
ISIN
FR0013280286
Symbol
BIM
Sector

Key metrics

Market capitalization €14.00b
Enterprise Value €14.04b
P/E (TTM) P/E ratio 32.39
EV/FCF (TTM) EV/FCF 43.68
EV/Sales (TTM) EV/Sales 3.53
P/S ratio (TTM) P/S ratio 3.52
P/B ratio (TTM) P/B ratio 3.33
Dividend yield 0.76%
Last dividend (FY24) €0.90
Revenue growth (TTM) Revenue growth 8.31%
Revenue (TTM) Revenue €3.98b
EBIT (operating result TTM) EBIT €567.80m
Free Cash Flow (TTM) Free Cash Flow €321.50m
EPS (TTM) EPS €3.67
P/E forward 27.23
P/S forward 3.28
EV/Sales forward 3.30
Show more

Is bioMerieux SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,792 stocks worldwide.

bioMerieux SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a bioMerieux SA forecast:

11x Buy
69%
3x Hold
19%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a bioMerieux SA forecast:

Buy
69%
Hold
19%
Sell
13%

Financial data from bioMerieux SA

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
3,980 3,980
8% 8%
100%
- Direct Costs 1,823 1,823
2% 2%
46%
2,157 2,157
14% 14%
54%
- Selling and Administrative Expenses 772 772
22% 22%
19%
- Research and Development Expense 492 492
7% 7%
12%
893 893
12% 12%
22%
- Depreciation and Amortization 326 326
16% 16%
8%
EBIT (Operating Income) EBIT 568 568
40% 40%
14%
Net Profit 432 432
21% 21%
11%

In millions EUR.

Don't miss a Thing! We will send you all news about bioMerieux SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The firm develops testing. detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.

Head office France
CEO Pierre Boulud
Employees 14,754
Founded 1967
Website www.biomerieux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today